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Abstract
Objectives: To explore the roles of Bcl-xl and Bcl-xs in the development and progression of endometrial
carcinoma, and to analyze the correlation between Bcl-xl and Bcl-xs.
Methods: RT-PCR and Western-blot assay were applied to detect the expressions of Bcl-xl and Bcl-xs in
endometrial tissues of various histomorphologic types.
Results: The Bcl-xl expression levels of simple and atypical hyperplasia endometrial tissues were not significantly
different from that of normal endometrial tissue (both P > 0.05). On contrary, Bcl-xl expression in endometrial
carcinoma tissue was significantly higher than the normal endometrial tissue (P = 0.00), which was correlated with
the pathological grading of endometrial carcinoma (F = 5.33, P = 0.02). In addition, Bcl-xs mRNA level in simple
hyperplasia endometrial tissue had no significant difference compared to that in normal endometrial tissue (P =
0.12), while the levels of atypical hyperplasia and endometrial carcinoma endometrial tissues were significantly
different from the normal endometrial tissue (both P = 0.00). Furthermore, level of Bcl-xs mRNA was correlated
with the clinical staging and lymph node metastasis of the endometrial carcinoma (P < 0.05). The expressions of
Bcl-xl and Bcl-xs were negatively correlated with each other (r = -0.76).
Conclusion: The abnormal expressions of Bcl-xs and Bcl-xl were one of the molecular mechanisms for the
pathogenesis of endometrial carcinoma, and altered ratio between these two might involve in the onset of
endometrial carcinoma.
Introduction
Endometrial carcinoma is one of the common malignant
tumors of female genital tract. The incidence of endo-
metrial carcinoma continued to increase annually and it
has replaced cervical cancer in some countries as the
most common malignant tumors of female genital tract
[1]. However, the molecular biological mechanisms
involved in the pathogenesis of endometrial carcinoma
remain unclear. Recent studies find that Bcl-2 family is
a major tumor suppressor gene family in association to
the pathogenesis of endometrial carcinoma. As a regula-
tory point for caspase activation and mitochondria func-
tion, Bcl-2 gene family functions as a common pathway
for transmission of cell apoptosis signals to regulate cell
survival and apoptosis[2]. There are at least 15 members
in the Bcl-2 family[3,4], among which Bcl-2 and Bcl-x
are major genes involving in the development and
progression of tumors and therefore attract much atten-
tions. Bcl-xl and Bcl-xs are encoded by Bcl-x gene,
where the abnormal expression of such in various
tumors including breast cancer, multiple myeloma and
thyroid cancer etc. has been reported in many domestic
and foreign literatures[5-7]. However, few report has
shown the levels of Bcl-xl and Bcl-xs in endometrial car-
cinoma tissue. The objective of this study was to investi-
gate the roles of Bcl-xl and Bcl-xs in the development
and progression of endometrial carcinoma.
Materials and methods
Material
Experimental group included endometrial tissues from
50 patients, who underwent surgery or hysteroscopy for
suspected endometrial lesions in the Department of
Obstetrics and Gynecology department in Shengjing
Hospital of China Medical University from December
2005 to October 2006, including 6 cases of simple
hyperplasia, 12 cases of atypical hyperplasia and
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metrial lesions were extracted for subsequent experi-
ments. Control group included normal endometrial
tissues from patients who underwent hysterectomy for
carcinoma of the cervix, including tissues in proliferative
phase(6 cases) and tissues in secretory phase(4 cases),
total of 10 cases. Patients in experimental group aged
34 ~70 years old with an average age of 52 ± 5.04 years
old, while the range of ages in control group was
37 ~59 years old with an average age of 48 ± 2.13 years
old. Patients did not receive radiotherapy, chemotherapy
or hormone therapy before the surgery and all cases
were confirmed by histopathology. 32 cases of endome-
trial carcinoma were graded for surgical and pathologic
stages according to the criteria in FIGO 1988: 22 cases
of stage I, 4 cases of stage II and 6 cases of stage III
endometrial carcinoma. Histological grading: 14 cases of
G1, 12 cases of G2 and 6 cases of G3 for endometrial
carcinoma. Myometrial invasion classification: 10 cases
in stage Ia, 16 cases in stage Ib and 6 cases in stage Ic.
Patients were also grouped according to the status of
lymph node metastasis: 6 cases with lymph node metas-
tasis and 26 cases free of lymph node metastasis.
Methods
RT-PCR technique to detect the expressions of Bcl-xl and
Bcl-xs mRNA
Total tissue RNA was extracted by following protocol
provided in the TRIzol reagent kit (DaLian TAKARA
Biotechnology Company). The 1
st strand of cDNA was
synthesized according to protocol provided in the
Reverse Transcription kit (Shanghai Invitrogen Biotech-
nology Co. Ltd.), while using a total of 15 μl of reaction
system with 1.5 μl template RNA. The cDNA product
was stored at -20°C for experiments. b-actin was included
as an internal control and PCR assay was performed
to amplify target genes. The volume of PCR reaction
system was 25 μl: 3 μl template cDNA, 2.5 μl 10 × buffer,
2 μl 2.5 mM dNTP, 0.1 μl of each primers, and 0.2 μl
5u / μl Taq-E and the total reaction volume was raised to
25 μl using deionized water. Bcl-xl primer sequences
were: upstream 5’-GGCAACCCATCCTGGCACCT-3’,
downstream 5’-AGCGTTCCTGGCCCTTTCG-3’, yield-
ing predicted amplification product of 472 bp. Bcl-xs
primer sequences were: upstream 5’-GAGGGAGG-
CAGGCGACGAGTTT-3’, downstream 5’-ATGGCGG-
CTGGACGGAGGAT-3’, yielding predicted amplification
product of 216 bp. b-actin primer sequences were:
upstream 5’-GTGGGGCGCCCCAGGCACCA-3, down-
stream 5’-CTCCTTAATGTCACGCACGATTTC-3’,
yielding predicted amplification product of 498 bp.
b-actin was used as internal control to normalize differ-
ent reactions. PCR reaction was performed on an
thermocycler (PTC-100™, USA). Amplification conditions
for Bcl-xl were: initial denaturation at 94°C for 3 min,
then proceeding with the following reaction conditions: a
total of 35 cycles of denaturation at 94°C for 45 s, anneal-
ing at 59°C for 45 s, and extension at 72°C for 60 s before
final extension at 72°C for 7 min. As for Bcl-xs, the pro-
cess included: initial denaturation at 94°C for 3 min, then
proceeding with the following reaction conditions: a total
of 35 cycles of denaturation at 94°C for 40 s, annealing at
60°C for 60 s, and extension at 72°C for 60 s, before final
extension at 72°C for 7 min. 5 μlP C Rp r o d u c tw a ss u b -
jected to 2% agarose gel electrophoresis (150 v) for 60
min and stained with ethidium bromide. RT-PCR ampli-
fication product was then observed under UV light.
FX174Hinc II (TAKARA Co.) was included as the stan-
dard for relative molecular size. 1D KodaK image analysis
software was used to observe and capture images. Optical
density (A) ratio of target gene and b-actin RT-PCR
amplification products was calculated to determine the
relative mRNA content of the target gene.
Western-blot assay to determine the expressions of Bcl-xl
and Bcl-xs/l protein
Cytosolic protein was extracted and sample OD
values were determined by phenol reagent assay
(0.305~1.254). All samples were adjusted to equal con-
centration and sampling buffer was added. Total of 40
ug protein was loaded onto 10% polyacrylamide gel for
2 h electrophoresis and b- a c t i nw a su s e da sl o a d i n g
control. After electric transferring, membrane was
washed with TBS once, blocked by TBS containing 5%
(v/v) skim milk overnight and then washed with TTBS
for 3 times, 5 min for each wash. Mouse anti-human
Bcl-xl monoclonal antibody and mouse anti-human
Bcl-xs/l monoclonal antibody were added (1:500 dilu-
tion for both antibodies in TTBS containing 1% BSA),
before 2 hours of incubation at room temperature.
Next, membranes were washed by TTBS for 3 times
and horseradish peroxidase-labeled mouse anti-rabbit
IgG secondary antibody was added (1:500 dilution),
The whole setup was incubated at room temperature
for 1 h and washed by TTBS for 3 times, 5 min for
each and finally washed by TBS for 5 min. An auto-
matic electrophoresis gel image analysis system (Chemi
Imageer 5500) was used to analyze optical intensities
of the protein bands. The equation of relative
optical density (A) = optical density of the target
protein/optical density of actin, was used to perform
semi-quantitative analysis.
Statistical analysis
SPSS13.0 statistical software was used to perform
unpaired t-test, one-way ANOVA and correlation analy-
sis. P < 0.05 was set as the criteria for statistical
significance.
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Expressions of Bcl-xl and Bcl-xs mRNA in different types
of endometrial tissues
RT-PCR result showed that tissues of expressed Bcl-xl
mRNA in order from low to high levels Bcl-xl mRNA
expressions were normal endometrium, simple hyperpla-
sia endometrial tissue, atypical hyperplasia endometrial
tissue, and endometrial carcinoma tissue (Fig. 1).
Although level of Bcl-xl mRNA was slightly unregulated
in simple hyperplasia endometrial tissue, it was not sig-
nificantly different than that of normal endometrial tis-
sue (t =- 1 . 5 1 ,P > 0.05). In addition, no significant
difference was detected between Bcl-xl mRNA level of
atypical hyperplasia endometrial tissue and that of nor-
mal endometrium (t = 0.90, P > 0.05). On contrary, Bcl-
xl expression in endometrial carcinoma tissue was sig-
nificantly higher than in normal endometrial tissue (t =
15.44, P < 0.05). Expression of Bcl-xl mRNA was not
correlated with clinical staging, myometrial invasion and
lymph node metastasis of the endometrial carcinoma,
but correlated with histological grade (F = 5.33, P =
0.02) (Table 1).
Furthermore, tissues of expressed Bcl-xl mRNA in
order from low to high levels Bcl-xs mRNA levels were
normal endometrium, simple hyperplasia endometrial
tissue, atypical hyperplasia endometrial tissue and endo-
metrial carcinoma tissue (Fig. 2). Although its expres-
sion was slightly elevated in simple hyperplasia
endometrial tissue, no significant difference was
detected compared to normal endometrial tissue (t =
1.80, P > 0.05). On contrary, its expression was signifi-
cantly different between atypical hyperplasia endometrial
tissue and normal endometrium (t =5 . 1 7 ,P < 0.05). In
addition, Bcl-xs expression in endometrial carcinoma
tissue was significantly higher than that in normal endo-
metrium (t = 6.88, P < 0.05) (Table 1). Expression level
of Bcl-xs mRNA was correlated with clinical staging and
lymph node metastasis of the endometrial carcinoma,
but not related to myometrial invasion and pathological
staging.
Expressions of Bcl-xl and Bcl-xs/l protein in different
types of endometrial tissues
Immunoblotting results showed that Bcl-xl protein
expression had matched pattern with expression of Bcl-
xl mRNA in different types of endometrial tissues, For
example, these two were positively correlated (r = 0.44,
P = 0.015). In other words, expressions of these two
proteins were relatively low in normal endometrial tis-
sue, while elevated expression could be detected in both
simple hyperplasia and atypical hyperplasia endometrial
tissues (Fig. 3). In addition, expressions of Bcl-xl and
Bcl-xs/l proteins did not show a significant difference
between simple hyperplasia and normal endometrial tis-
sues (t = -0.61, P > 0.05) and the expression in atypical
hyperplasia endometrial tissue was not significantly dif-
ferent from that in normal endometrial tissue (t =- 0 . 6 1 ,
P > 0.05). Expressions of Bcl-xl and Bcl-xs/l proteins
were further upregulated in endometrial carcinoma tis-
sue to a level significantly different from that of normal
endometrial tissue (t = -2.22, P = 0.04). Furthermore,
expression of Bcl-xl protein correlated with pathological
staging of the tissue sample (see Table 2). Trend of Bcl-
xs/l protein expressions in different types of endometrial
tissues matched that of Bcl-xs mRNA expression. Speci-
fically, no significant difference was found in Bcl-xs/l
protein between simple hyperplasia and normal endo-
metrial tissues (t =0 . 3 3 ,P = 0.75). However, significant
differences of Bcl-xs/l expression were detected between
normal endometrial tissue and atypical hyperplasia
endometrial tissue (t = 2.42, P =0 . 0 4 ) ,a sw e l la s
between normal endometrial tissue and endometrial car-
cinoma tissue (t =4 . 1 4 ,P = 0.00) (Fig. 4). Expression of
Bcl-xs/l protein did not correlated with degree of myo-
metrial invasion and pathological staging, but signifi-
cantly correlated with clinical staging and lymph node
metastasis of the sample (see Table 2).
Correlation analysis between Bcl-xl and Bcl-xs
Correlation analysis identified a negative correlation
between Bcl-xl gene and Bcl-xs gene in different types
Figure 1 Bcl-xl mRNA(RT-PCR). 1, 2: Normal endometrium; 3, 4: Simple hyperplasia endometrial tissue, 5, 6: Atypical hyperplasia endometrial
tissue; 7~12: Endometrial carcinoma tissue.
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tein was negatively correlated with expression of Bcl-xs/l
protein (r = -0.39, P = 0.04) and Bcl-xs gene was posi-
tively correlated with Bcl-xs/l protein expression (r =
0.73, P = 0.00).
Discussion
As a member of Bcl-2 gene family, role of Bcl-x in the
development and progression of tumors has received
more and more attentions. Bcl-x gene was cloned by
Boise[8] in 1993 by screening a chicken lymphocyte
cDNA library using mouse Bcl-2 cDNA as the probe.
Bcl-x has dual regulatory roles after activation. It is loca-
lized at 20q11.21 and a different splicing site at the 5’
terminus of its 1
st mRNA exon leads to two fragments:
a longer fragment Bcl-xl and a shorter fragment Bcl-xs.
In recent years, expression of Bcl-x gene products (Bcl-
xl and Bcl-xs) in some tumors has been reported in
domestic and foreign studies. However, the expression
status in endometrial carcinoma tissue has rarely been
characterized yet.
Expression of Bcl-xl in endometrial carcinoma tissue and
the significances
Bcl-xl contains 241 amino acids and BH1-BH4 4 homo-
logous sequences. Its sequence is 43% identical to that
of Bcl-2 and their functions are similar too. Bcl-xl could
inhibit cell apoptosis through forming heterodimer with
Bax in cytosol. Studies found that Bcl-xl could inhibit
apoptosis in a Bcl-2-independent manner. It could inhi-
bit cell apoptosis mediated by many apoptosis-inducing
Table 1 Contents of Bcl-xl and Bcl-xs mRNA in different types of endometrial tissue and correlation with pathological
parameters of the endometrial carcinoma
Classification Bcl-xl mRNA expression Bcl-xs mRNA expression
c ±S P value c ±S P value
Normal endometrium 0.35 ± 4.37 0.93 ± 3.05
Simple hyperplasia 0.38 ± 3.25 0.13 0.89 ± 2.00 0.12
Atypical hyperplasia 0.37 ± 3.93 0.38 0.68 ± 0.10 0.00
Endometrial carcinoma 0.75 ± 0.13 0.00 0.49 ± 0.14 0.00
Degree of Pathological Differentiation
Well-differentiated 0.85 ± 7.23 0.52 ± 0.14
Moderately-differentiated 0.70 ± 7.60 F = 5.33 0.45 ± 0.16 F = 0.40
Poorly-differentiated 0.70 ± 1.44 P = 0.02 0.48 ± 7.57 P = 0.68
Clinical Staging
Stage I 0.74 ± 0.15 0.55 ± 7.67
Stage II 0.79 ± 0.10 F = 0.57 0.41 ± 2.83 F = 30.87
Stage III 0.82 ± 0.15 P = 0.58 0.21 ± 7.77 P = 0.00
Lymph Node Metastasis
No 0.82 ± 0.16 F = 2.31 0.51 ± 9.16 F = 0.64
Yes 0.79 ± 0.10 P = 0.73 0.25 ± 6.70 P = 0.00
Depth of Myometrial Invasion
0 0.82 ± 7.26 0.58 ± 7.07
≤ 1/2 0.76 ± 0.11 F = 3.22 0.45 ± 0.16 F = 1.73
> 1/2 0.64 ± 4.73 P = 0.07 0.45 ± 6.03 P = 0.22
Figure 2 Bcl-xs mRNA(RT-PCR). 1, 2: Normal endometrium; 3, 4:
Simple hyperplasia endometrial tissue, 5, 6: Atypical hyperplasia
endometrial tissue; 7~12: Endometrial carcinoma tissue.
Figure 3 Expression of Bcl-xl protein in different types of
endometrial tissues. 1, 2: Normal endometrium; 3, 4: Simple
hyperplasia endometrial tissue, 5~7: Atypical hyperplasia
endometrial tissue; 8~10: Endometrial carcinoma tissue.
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sis. Bcl-xl protein was highly expressed in some tumors
with low level of Bcl-2. Some researchers believed that
Bcl-xl protein might have substituted the function of
Bcl-2 in some tumors. Under certain condition, this pro-
tein has stronger apoptosis-inhibitory effect over Bcl-2,
indicating the key role of Bcl-xl in the process of cell
transformation.
Studies showed that tumor cell apoptosis could be
induced by lowering the Bcl-xl expression in human
prostate cancer tissue[9]. Furthermore, researches
demonstrated that induction of tumor cell apoptosis
could be achieved through inhibiting the expression of
Bcl-xl in malignant pleural mesothelioma[10]. Boehm-
denf et al. [11]also showed that Bcl-xl expression in
head and neck squamous cell carcinoma was signifi-
cantly different among different types of pathological
grading, while the expression of Bcl-xl protein in
human prostate cancer specimens was closely corre-
lated with the Gleason scoring and metastasis of
human prostate cancers[12]. Therefore, Bcl-xl plays an
important role in pathogenesis of tumor as an anti-
apoptotic factor, and chemotherapy-resistance of the
tumor cell may be associated with high level of Bcl-xl
expression [13,14].
Our study found that expressions of Bcl-xl mRNA
and protein were slightly increased in simple hyperpla-
sia and atypical hyperplasia endometrial tissues, while
significantly increased in endometrial carcinoma tissue.
In addition, Bcl-xl expression was correlated with the
pathological grading of endometrial carcinoma, sug-
gesting that elevation in Bcl-xl disrupted the regulation
of signal transduction and normal gene expression,
while it led to abnormal endometrial cell proliferation
differentiation and eventually endometrial carcinoma.
Therefore, we concluded that apoptotic inhibition
caused by abnormal Bcl-xl expression might be one of
the pathogenetic mechanisms of endometrial carci-
noma, and this abnormal expression might also be
associated with the malignant behaviors of endometrial
carcinoma.
Figure 4 Expression of Bcl-xs/l protein in different types of
endometrial tissue. 1, 2: Normal endometrium; 3, 4: Simple
hyperplasia endometrial tissue, 5~7: Atypical hyperplasia
endometrial tissue; 8~10: Endometrial carcinoma tissue.
Table 2 Contents of Bcl-xl and Bcl-xs/l protein in different types of endometrial tissue and correlation with
pathological parameters of the endometrial carcinoma
Classification Bcl-xl protein expression Bcl-xs/l protein expression
c ±S P value c ±S P value
Normal endometrium 41.00 ± 21.05 105.60 ± 33.05
Simple hyperplasia 49.00 ± 11.36 0.57 96.00 ± 50.48 0.75
Atypical hyperplasia 49.00 ± 11.36 0.56 73.00 ± 4.47 0.04
Endometrial carcinoma 90.88 ± 48.33 0.04 54.50 ± 18.49 0.00
Degree of Pathological Differentiation
Well-differentiated 109.29 ± 39.06 57.71 ± 22.33
Moderately-differentiated 71.50 ± 13.53 F = 4.65 56.50 ± 17.81 F = 0.32
Poorly-differentiated 56.67 ± 17.21 P = 0.03 46.67 ± 4.04 P = 0.74
Clinical Staging
Stage I 85.17 ± 50.83 61.17 ± 16.03
Stage II 108.00 ± 48.08 F = 0.30 45.50 ± 2.12 F = 4.02
Stage III 108.00 ± 52.33 P = 0.74 30.50 ± 6.36 P = 0.04
Lymph Node Metastasis
No 88.43 ± 49.33 F = 0.06 55.43 ± 21.58 F = 0.95
Yes 108.00 ± 52.33 P = 0.61 30.00 ± 5.66 P = 0.02
Depth of Myometrial Invasion
0 76.80 ± 18.78 65.60 ± 19.92
≤ 1/2 86.00 ± 38.58 F = 1.13 52.25 ± 18.55 F = 1.34
> 1/2 127.33 ± 94.99 P = 0.35 46.67 ± 2.52 P = 0.30
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endometrial carcinoma and the significances
B c l - x sh a s6 3a m i n oa c i d sl e s st h a nB c l - x l( B H 1a n d
BH2 region). Its function is similar to that of Bax, which
is to inhibit Bcl-2 activity and promote cell apoptosis[4].
S u m a n t r a ne ta l .[ 5 ]u s e da d e n o v i r u s e sa sv e c t o rt o
introduce Bcl-xs into breast cancer cell line. Their
results showed that adv-Bcl-xs transfection could induce
tumor cell apoptosis. In 1996, Ealovega et al. [15]con-
structed a replication-deficient adenovirus as vector to
transiently express Bcl-xs in MCF-7 human breast can-
cer cell line and nude mice breast cancer tissues. They
found that Bcl-xs overexpression could induce apoptosis
of MCF-7 cells. Further studies have shown that adv-
Bcl-xs could infect breast cancer cells in vitro or in vivo
to induce growth inhibition and death of breast cancer
cells. This inhibitory and pro-apoptotic effects were
more prominent with increased virus titer and increased
Bcl-xs gene copies carried by the virus[16]. Our results
showed that expressions of Bcl-xs mRNA and Bcl-xs/l
protein slightly decreased in normal and simple hyper-
plasia endometrial tissues, while significantly decreased
in atypical hyperplasia and endometrial carcinoma tis-
sues, suggesting that abnormal expressions of these two
played important roles in the early stage of endometrial
carcinoma development. It was possible that low-expres-
sion of Bcl-xs led to inhibition of apoptosis, and thus
abnormal endometrial cells threatening the body func-
tion could not be eliminated, resulting in endometrial
carcinoma.
The correlation between expressions of Bcl-xl and Bcl-xs
in different types of endometrial tissues
Bcl-xs can form heterodimer with Bcl-xl. Ratio of these
two affects the sensitivity and resistance of cells to
variety of apoptotic factors and determines the activity
of caspases, which are the final pathway for apoptosis
in many different cells. Many Bcl-2 gene family mem-
bers form a system with other members to modulate
apoptosis, especially Bcl-2, Bcl-xs and Bax. Qiang
Wang et al. [17] used in situ hybridization to test the
expression statuses of Bcl-xl and Bcl-xs in post-
ischemic brain tissue undergoing mild hypothermia
treatment. They confirmed that ratio between Bcl-xl
and Bcl-xs concentrations determined whether apopto-
sis would occur or not. The expression of Bcl-xl and
Bcl-xsm in different types of endometrial tissues were
negatively correlated. We speculate that it might be
B c l - x sn o tB c l - x le x p r e s s i o nt h a ti sd o m i n a n ti nn o r -
mal endometrial tissue. With progression of endome-
trial lesion, Bcl-xl expression increased while Bcl-xs
expression decreased gradually. When Bcl-xl expres-
sion becomes dominant, endometrial carcinoma will be
induced. The ratio between these two has certain
impact on the development of endometrial cancer.
S i n c en os p e c i f i cB c l - x sa n t i b o d yi sa v a i l a b l en o w ,w e
could not detect its expression directly using Western
blot. In our study, we used Bcl-xs/l antibody that recog-
nized a common motif of Bcl-xl and Bcl-xs, and primar-
ily the motif in Bcl-xs. Our result suggested that
expression of Bcl-xs/l was low in endometrial lesion tis-
sue of high Bcl-xl expression, implying low expression
of Bcl-xs in these tissues.
In summary, our results suggested that abnormal ele-
vation of Bcl-xl expression and abnormal decrease of
Bcl-xs expression played an important role in the devel-
opment of endometrial carcinoma. When malignant bio-
logical behaviors of endometrial carcinoma developded,
Bcl-xs gene expression was significantly decreased, pro-
viding a new tumor marker for the early diagnosis of
endometrial carcinoma. Further studies on the action
mechanisms of Bcl-xl and Bcl-xs gene should provide
new molecular targets for gene therapy of endometrial
carcinoma.
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